Analysis of genetic polymorphism relating to interstitial lung disease events in with advanced pancreatic cancer patients receiving gemcitabine plus erlotinib

Not Applicable

• Conditions: advanced pancreatic cancer

• Registration Number: JPRN-UMIN000009003
• Lead Sponsor: Kobe University Hospital

Brief Summary

The combination of HLA-B*15:01 and DRB1*15:01 suggested to be associated with ILD in Japanese patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-09-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1)Pregnancy,lactational woman.Man hope who's partner's pregnancy. 2)Patients who have a concurrent or previous interstitial lung disease, idiopathic pulmonary fibrosis, pneumoconiosis,drug-induced pneumonia. 3)Patients who have a concurrent or previous pulmonary emphysema or chronic obstructive pulmonary disease. 4)Patients who are after resection one lung. 5)Patients who have a history of radiation to the chest. 6)Patients who have received gemcitabine within 3 months. 7)Patients who had previously been exposed to EGFR inhibitor. 8)Patients who received transfusion within 4 weeks before registry. 9)Patients who have the follows digestive tract damage. patients who can't take a pill. patients wfo have active ulcer. 10)Patients who have clinically problematical oculus disease(serious xerosis,keratoconjunctivitis sicca, keratitis). 11)Patients who have symptomatic metastatic brain tumor. 12)Patients who have active bacterium or fungus infections. 13)Patients who have a concurrent clinically problematical heart disease(uncontroled hypertension,unstable angina, congestive heart failure,severe arrhythmia,myocarcial infraction within 12 months before registry). 14)Patients who have a current uncontroled diabetes mellitus. 15)Patients who have massive humor pool or edema. 16)Patiens who have previous severe drug-induced allergy. 17)In cases of doctor judged inappropriate for this protocol.

Study & Design

• Study Type: Observational
• Study Design: Not specified